A. Turpie

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Thromboprophylaxis with dalteparin in medical patients: which patients benefit?

S. Goldhaber, A. Turpie, A. Cohen, 2007, Vascular medicine.

Efficacy and Safety of Fixed Low-Dose Dalteparin in Preventing Venous Thromboembolism Among Obese or Elderly Hospitalized Patients

S. Goldhaber, A. Turpie, N. Kucher, 2005 .

Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial.

S. Goldhaber, A. Turpie, N. Kucher, 2005, Archives of internal medicine.

Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients

S. Goldhaber, A. Turpie, A. Cohen, 2004, Thrombosis and Haemostasis.

Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen.

J. Douketis, A. Turpie, J. A. Johnson, 2004, Archives of internal medicine.

Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice

A. Turpie, J. Beyer-Westendorf, P. Mouret, 2017, Orthopedic research and reviews.

The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.

M. Gent, B. Eriksson, A. Turpie, 2012, The Journal of bone and joint surgery. British volume.

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.

V. Hasselblad, J. Douketis, R. Becker, 2015, The New England journal of medicine.

Postoperative Low‐Molecular‐Weight Heparin Bridging Is Associated with an Increase in Wound Hematoma Following Surgery for Pacemakers and Implantable Defibrillators

J. Healey, S. Connolly, C. Morillo, 2009, Pacing and clinical electrophysiology : PACE.

Periprocedural Management of Antithrombotic Therapy and Use of Bridging Anticoagulation

G. Raskob, A. Nicolaides, M. Griffin, 2008, International Angiology.

Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry).

J. Douketis, A. Turpie, A. Dunn, 2008, The American journal of cardiology.

Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.

B. Eriksson, A. Turpie, K. Bauer, 2002, Archives of internal medicine.

Perioperative management of patients receiving oral anticoagulants: a systematic review.

A. Turpie, A. Dunn, 2003, Archives of internal medicine.

Enoxaparin Is Effective and Safe as Bridging Anticoagulation in Patients with a Mechanical Prosthetic Heart Valve who Require Temporary Interruption of Warfarin because of Surgery or an Invasive Procedure.

J. Douketis, A. Turpie, 2004 .

Clinical outcomes with unfractionated heparin or low‐molecular‐weight heparin as bridging therapy in patients on long‐term oral anticoagulants: the REGIMEN registry 1

J. Douketis, J. Spandorfer, A. Turpie, 2006, Journal of thrombosis and haemostasis : JTH.

Brief Communication: Preoperative Anticoagulant Activity after Bridging Low-Molecular-Weight Heparin for Temporary Interruption of Warfarin

M. O’Donnell, A. Turpie, C. Kearon, 2007, Annals of Internal Medicine.

14 Antithrombotic treatment of cerebrovascular disease

W. Oczkowski, A. Turpie, 1990 .

Venous thromboembolism management: where do novel anticoagulants fit?

A. Turpie, A. Spyropoulos, 2013, Current medical research and opinion.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

W. Ageno, A. Turpie, J. Lieberman, 2008, The New England journal of medicine.

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban — an Oral, Direct Factor Xa Inhibitor — in Patients Undergoing Major Orthopaedic Surgery

M. Gent, B. Eriksson, A. Turpie, 2008, Clinical pharmacokinetics.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

M. Gent, A. Turpie, K. Bauer, 2009, The Lancet.

Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor

B. Norrving, A. Turpie, R. Kreutz, 2012, Thrombosis and Haemostasis.

Comparison of a daily fixed 2.5-mg warfarin dose with a 5-mg, international normalized ratio adjusted, warfarin dose initially following heart valve replacement.

W. Ageno, A. Turpie, A. Venco, 2001, The American journal of cardiology.

New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF

A. Parkhomenko, D. Fitzmaurice, B. Gersh, 2019, European heart journal. Cardiovascular pharmacotherapy.

Unstable angina and non-ST-elevation myocardial infarction: initial antithrombotic therapy and early invasive strategy.

C. Cannon, A. Turpie, 2003, Circulation.

Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study

C. Francis, S. Goldhaber, T. Ortel, 2015, Journal of thrombosis and haemostasis : JTH.

Prediction of Deep Vein Thrombosis after Elective Hip Replacement Surgery by Preoperative Clinical and Haemostatic Variables: The ECAT DVT Study

G. Lowe, R. Turner, P. Mannucci, 1999, Thrombosis and Haemostasis.

ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction

R. Collins, M. Keltai, B. Lewis, 1995, The Lancet.

Replacement of venography in suspected venous thrombosis by impedance plethysmography and 125I-fibrinogen leg scanning: a less invasive approach.

D. Sackett, J. Hirsh, D. Taylor, 2020, Annals of internal medicine.

New Antithrombotic Drugs: Beyond Aspirin and Heparin

A. Turpie, 1999 .

Screening computer‐assisted dosage programs for anticoagulation with warfarin and other vitamin K antagonists: minimum safety requirements for individual programs

D. Fitzmaurice, W. Ageno, A. Turpie, 2009 .

Multidetector-row computed tomography in suspected pulmonary embolism.

A. Turpie, 2005, The New England journal of medicine.

Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry

W. Ageno, L. Mantovani, P. Prandoni, 2018, Thrombosis and Haemostasis.

The Diagnosis of Acute, Recurrent, Deep‐vein Thrombosis: A Diagnostic Challenge

M. Gent, P. Powers, A. Turpie, 1983, Circulation.

A comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients.

H. Büller, J. T. ten Cate, A. Turpie, 1993, The New England journal of medicine.

Heparin-Induced Thrombocytopenia

G. Raskob, A. Nicolaides, M. Griffin, 2013, Thrombosis and Haemostasis.

Clinical usefulness of testing for a heparin-dependent platelet-aggregating factor in patients with suspected heparin-associated thrombocytopenia.

J. Kelton, P. Powers, A. Turpie, 1984, The Journal of laboratory and clinical medicine.

Deep‐vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography

A. Turpie, Ching‐Jen Wang, L. Lee, 2005, Journal of thrombosis and haemostasis : JTH.

Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model.

A. Skene, J. Halperin, A. Turpie, 2011, Blood.

Treatment for Patients With Cancer

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Diagnosis and Anticoagulant Treatment *

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Key Questions to be Answered

G. Raskob, A. Nicolaides, M. Griffin, 2013 .

Changes in platelet behaviour during arvin therapy.

A. S. Douglas, A. Turpie, C. Prentice, 1969, Lancet.

Etiology of Stroke

Panel, C. Kase, J. Mohr, 1997 .

Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation

J. Halperin, A. Turpie, P. Steg, 2016, Thrombosis and Haemostasis.

Rivaroxaban: un anti-thrombotique original

R. Giugliano, A. Turpie, J. Alexander, 2012 .

Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm?

J. Halperin, A. Turpie, C. Kessler, 2012, Journal of thrombosis and haemostasis : JTH.

Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co‐medication interactions

L. Mantovani, A. Turpie, R. Kreutz, 2016, British journal of clinical pharmacology.

Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation

D. Fitzmaurice, B. Gersh, A. Camm, 2020, JAMA network open.

Spotlight on real-world evidence for the treatment of DVT: XALIA

W. Ageno, A. Turpie, 2016, Thrombosis and Haemostasis.

Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.

W. Ageno, L. Mantovani, A. Turpie, 2016, The Lancet. Haematology.

Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD‐AF Registry

A. Tsiatis, D. Fitzmaurice, A. Camm, 2021, Journal of thrombosis and haemostasis : JTH.

Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry.

A. Camm, L. Mantovani, S. Goldhaber, 2019, JAMA cardiology.

Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation: Results From the GARFIELD-AF Registry

D. Fitzmaurice, W. Hacke, A. Camm, 2019, Circulation.

Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism.

A. Turpie, F. Spencer, M. Monreal, 2007, Chest.

Inferior Vena Cava Filters

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators.

A. Turpie, F. Spencer, M. Monreal, 2011, Chest.

Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.

R. Califf, M. Cohen, A. Langer, 2000, Journal of the American College of Cardiology.

Venous thromboembolism: pathophysiology, clinical features, and prevention

G. Lip, A. Turpie, B. Chin, 2002, BMJ : British Medical Journal.

ABC of antithrombotic therapy: Venous thromboembolism: pathophysiology, clinical features, and prevention

G. Lip, A. Turpie, B. Chin, 2002 .

Fondaparinux in the management of patients with ST-elevation acute myocardial infarction

A. Turpie, 2006, Vascular health and risk management.

Effect of gaboon viper (Bitis gabonica) venom on blood coagulation, platelets, and the fibrinolytic enzyme system

A. S. Douglas, J. C. Ferguson, C. Forbes, 1969, Journal of clinical pathology.

Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real‐world prospective study

A. Camm, P. Kirchhof, A. Camm, 2017, Clinical cardiology.

Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial.

J. Halperin, P. Steg, A. Turpie, 2022, JAMA.

Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART Study

A. Dans, A. Turpie, A. Cohen, 2005, Journal of thrombosis and haemostasis : JTH.

Prevention of venous thrombosis in patients with intracranial disease by intermittent pneumatic compression of the calf

W. Beattie, J. Hirsh, A. Turpie, 1977, Neurology.

The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE.

Alfredo E Farjat, W. Ageno, L. Mantovani, 2021, Thrombosis research.

Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD‐VTE patients

Alfredo E Farjat, W. Ageno, L. Mantovani, 2019, Journal of thrombosis and haemostasis : JTH.

Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.

R. Califf, M. Cohen, A. Langer, 1998, The American journal of cardiology.

Low-molecular-weight heparins in non–ST-segment elevation ischemia: the ESSENCE trial

R. Califf, A. Langer, S. Goodman, 1998 .

Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease

Alfredo E Farjat, W. Ageno, L. Mantovani, 2020, JAMA network open.

Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients

A. Turpie, T. Fuji, A. Lensing, 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Perioperative management of patients receiving oral anticoagulants.

A. Turpie, A. Dunn, 2003 .

industry-sponsored clinical trials: the ARO-CRO model Improving academic leadership and oversight in large

A. Skene, J. Halperin, A. Turpie, 2011 .

Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility

E. Vicaut, R. Yusen, A. Turpie, 2010, Annals of Internal Medicine.

Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial

M. Prins, A. Turpie, A. Cohen, 2006, BMJ : British Medical Journal.

Sensitivity and Specificity of a Rapid Whole-Blood Assay for D-Dimer in the Diagnosis of Pulmonary Embolism

J. Hirsh, P. Brill-Edwards, M. Gent, 1998, Annals of Internal Medicine.

Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points.

B. Eriksson, A. Turpie, K. Bauer, 2004, Chest.

Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty

M. Gent, B. Eriksson, A. Turpie, 2010, Thrombosis and Haemostasis.

Low-Molecular-Weight Heparins in Acute Unstable Coronary Artery Disease – An Update

A. Turpie, 1999, Pathophysiology of Haemostasis and Thrombosis.

Venous Thromboembolism: Pathophysiology, Diagnosis, and Prophylaxis

W. Ageno, A. Turpie, M. Donadini, 2012 .

Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE

Alfredo E Farjat, W. Ageno, L. Mantovani, 2021, TH Open.

Comparison of Low-Intensity Warfarin Therapy With Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism

M. Gent, A. Turpie, S. Kahn, 2004 .

MECHANICAL VALVES. AUTHORS' REPLY

G. E. Miller, V. Gott, T. David, 1996 .

A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.

A. Turpie, A. Gallus, J. Hoek, 2001, The New England journal of medicine.

Therapy of unstable angina with the low molecular weight heparins

W. Ageno, A. Turpie, 2000, Vascular medicine.

Low-Molecular-Weight Heparin in Acute Coronary Syndromes

M. O’Donnell, A. Turpie, 2004, Heart Drug.

New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins.

W. Ageno, A. Turpie, 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Choice of low molecular weight heparins

A. Turpie, 2003, Journal of thrombosis and haemostasis : JTH.

Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?

G. Karthikeyan, J. Hirsh, J. Eikelboom, 2009, British journal of haematology.

The design of venous thromboembolism prophylaxis trials: Fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery

A. Turpie, 2004, International journal of clinical practice.

Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery

L. Mantovani, A. Turpie, R. Kreutz, 2012, Vascular health and risk management.

Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study

D. Ward, R. Rothlein, B. Eriksson, 2008, Journal of thrombosis and haemostasis : JTH.

Plasma betathromboglobulin and serum fragment E in acute partial stroke

A. Turpie, R. Bloch, E. Genton, 1982, British journal of haematology.

Fondaparinux, the first selective factor Xa inhibitor

B. Eriksson, A. Turpie, K. Bauer, 2003, Current opinion in hematology.

Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study.

A. Turpie, D. George, G. Agnelli, 2013, The bone & joint journal.

Management strategies in unstable coronary artery disease—Current problems and future directions

J. Cleland, D. Waters, A. Maseri, 1999, Clinical cardiology.

Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery.

C. Colwell, A. Turpie, L. Kwong, 2006, The Journal of arthroplasty.

Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy

A. Turpie, 2004, Expert opinion on pharmacotherapy.

Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism

B. Eriksson, A. Turpie, K. Bauer, 2002, Current opinion in pulmonary medicine.

Anticoagulant therapy after acute myocardial infarction.

A. Turpie, 1990, The American journal of cardiology.

Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients

A. Turpie, A. Cohen, V. Tapson, 2005, Thrombosis and Haemostasis.

Safer anticoagulant therapy after heart valve replacement. Recommendations for less intense regimens.

A. Turpie, A. G. G. Turpie, 1997, Postgraduate medicine.

New therapeutic opportunities for heparins: What does low molecular weight heparin offer?

A. Turpie, 2004, Journal of Thrombosis and Thrombolysis.

Pharmacology of the low-molecular-weight heparins.

A. Turpie, 1998, American heart journal.

New frontiers in the management of unstable coronary artery disease.

A. Turpie, 1997, The American journal of cardiology.

Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real‐world prospective study

P. Kirchhof, A. Camm, P. Amarenco, 2017, Clinical cardiology.

Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study

A. Camm, P. Kirchhof, P. Amarenco, 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD‐VTE

Alfredo E Farjat, W. Ageno, L. Mantovani, 2021, Journal of thrombosis and haemostasis : JTH.

Prophylaxis and therapy of venous thromboembolism.

J. Hirsh, A. Turpie, 1979, CRC critical reviews in clinical laboratory sciences.

Oral Direct Factor Xa Inhibitors

A. Turpie, 2016 .

Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment

A. Turpie, D. Purdham, A. Ciaccia, 2017, Therapeutic advances in cardiovascular disease.

The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery – subgroup analyses from 17,701 patients in the XAMOS study

L. Mantovani, A. Turpie, R. Kreutz, 2016, Vascular health and risk management.

Antithrombotic Therapy in Coronary Ischaemia: The Expanding Role of Low-Molecular-Weight Heparin

A. Turpie, 1998, Pathophysiology of Haemostasis and Thrombosis.

Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE

Alfredo E Farjat, W. Ageno, L. Mantovani, 2020, Journal of Thrombosis and Thrombolysis.

Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach

J. Halperin, A. Turpie, C. Kessler, 2013, Journal of thrombosis and haemostasis : JTH.

Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS‐ACTS Substudy

A. Camm, P. Kirchhof, A. Camm, 2016, Clinical cardiology.

A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery

M. Prins, B. Eriksson, A. Turpie, 2007, Journal of thrombosis and haemostasis : JTH.

A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)

M. Gent, A. Turpie, K. Bauer, 2008, Thrombosis and Haemostasis.

BAY 59‐7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose‐ranging study

M. Gent, A. Turpie, K. Bauer, 2005, Journal of thrombosis and haemostasis : JTH.

Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies

M. Gent, B. Eriksson, A. Turpie, 2007, Thrombosis and Haemostasis.

YM150, an Oral Direct Factor Xa Inhibitor, as Prophylaxis for Venous Thromboembolism in Patients with Elective Primary Hip Replacement Surgery. A Dose Escalation Study.

M. Prins, B. Eriksson, A. Turpie, 2005 .

The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: an evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients.

S. Goldhaber, R. Grimm, J. Heit, 2005, American heart journal.

New AI Prediction Model Using Serial PT-INR Measurements in AF Patients on VKAs: GARFIELD-AF.

A. Parkhomenko, D. Fitzmaurice, B. Gersh, 2019, European heart journal. Cardiovascular pharmacotherapy.

American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Etiology of stroke.

C. Kase, J. Mohr, G. Albers, 1997, Stroke.

Selective factor Xa inhibition with fondaparinux: from concept to clinical benefit

A. Turpie, 2008 .

Superficial Vein Thrombosis

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

The safety of fondaparinux for the prevention and treatment of venous thromboembolism

A. Turpie, 2005, Expert opinion on drug safety.

Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial

W. Ageno, R. Lopes, A. Turpie, 2022, The Lancet Haematology.

Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients

A. Turpie, L. Kwong, 2015, Current orthopaedic practice.

Emerging oral antiplatelet receptor inhibitors

J. Eikelboom, A. Turpie, L. Linkins, 2008 .

Antithrombotic therapy in the new millennium - the role of low-molecular-weight heparin

A. Turpie, 1999 .

Comparison of high-dose with low-dose aspirin in patients with mechanical heart valve replacement treated with oral anticoagulant.

A. Turpie, E. Gurfinkel, R. Altman, 1996, Circulation.

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)

J. Le Heuzey, J. Healey, J. Camm, 2019, Thrombosis Journal.

Systemic or Venous Thromboembolism Global Anticoagulant Registry in the Field – Venous Thromboembolism ( GARFIELD-VTE ) Rationale and design

W. Ageno, L. Mantovani, P. Prandoni, 2016 .

XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis

W. Ageno, L. Mantovani, A. Turpie, 2014, Thrombosis Journal.

Rivaroxaban for the prevention and treatment of venous thromboembolism

A. Turpie, 2012, Fundamental & clinical pharmacology.

Anticoagulation and enoxaparin use in patients with prosthetic heart valves and/or pregnancy. Report and Recommendations of the Anticoagulation in Prosthetic Valves and Pregnancy Consensus Report (APPCR) Panel and Scientific Roundtable

E. Topol, S. Goldhaber, R. Grimm, 2002 .

Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4

M. Gent, A. Turpie, K. Bauer, 2008 .

Advances in Antithrombotic Therapy: Novel Agents

J. Hirsh, A. Turpie, J. Weitz, 1995, Thrombosis and Haemostasis.

A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery

G. Raskob, B. Eriksson, A. Turpie, 2010, Thrombosis and Haemostasis.

Use of plasminogen activators in venous thrombosis

J. Hirsh, A. Turpie, 1990, World Journal of Surgery.

The Problem and the Need for Prevention

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE

Alfredo E Farjat, W. Ageno, L. Mantovani, 2021, Research and practice in thrombosis and haemostasis.

Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD‐VTE

Alfredo E Farjat, W. Ageno, L. Mantovani, 2021, Journal of thrombosis and haemostasis : JTH.

Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA‐LEA noninterventional studies

W. Ageno, L. Mantovani, A. Turpie, 2021, Research and practice in thrombosis and haemostasis.

Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry

Alfredo E Farjat, W. Ageno, L. Mantovani, 2019, Thrombosis and Haemostasis.

Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry

Alfredo E Farjat, W. Ageno, L. Mantovani, 2019, Thrombosis and Haemostasis.

Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty

J. Berlin, A. Turpie, S. Berkowitz, 2014, Vascular health and risk management.

Global Anticoagulant Registry in the Field – Venous Thromboembolism (GARFIELD-VTE)

W. Ageno, L. Mantovani, P. Prandoni, 2016, Thrombosis and Haemostasis.

Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study.

W. Ageno, L. Mantovani, A. Turpie, 2017, Thrombosis research.

Prevention of venous thromboembolism in medically ill patients: a clinical update

A. Turpie, A. Leizorovicz, 2006, Postgraduate Medical Journal.

Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study.

A. Turpie, A. Cohen, M. Samama, 2004, Archives of pathology & laboratory medicine.

Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX‐2)

M. Prins, B. Eriksson, A. Turpie, 2010, Journal of thrombosis and haemostasis : JTH.

Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis

W. Ageno, L. Mantovani, A. Turpie, 2018, TH Open.

Preoperative Enoxaparin Versus Postoperative Semuloparin Thromboprophylaxis in Major Abdominal Surgery: A Randomized Controlled Trial

A. Turpie, D. George, G. Agnelli, 2014, Annals of surgery.

The Ultra-Low-Molecular-Weight Heparin Semuloparin for Prevention of Venous Thromboembolism In Patients Undergoing Major Abdominal Surgery

A. Turpie, D. George, G. Agnelli, 2010 .

Clinical trials of deep vein thrombosis prophylaxis in medical patients.

W. Ageno, A. Turpie, 2005, Clinical cornerstone.

Multidetector-row computed tomography in suspected pulmonary embolism.

A. Turpie, 2005, The New England journal of medicine.

ORGARAN Extending the Frontiers of Venous Thrombosis Prophylaxis

M. Danhof, J. Hirsh, H. Adams, 1992 .

Thromboprophylaxis After Major Orthopaedic Surgery: State of the Art

A. Turpie, 2009 .

Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.

M. Gent, B. Eriksson, A. Turpie, 2009, The Journal of bone and joint surgery. British volume.

AVE5026, a new hemisynthetic ultra‐low‐molecular‐weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery – TREK: a dose‐ranging study

A. Turpie, P. Mismetti, M. Lassen, 2009, Journal of thrombosis and haemostasis : JTH.

Perioperative bridging interruption with heparin for the patient receiving long-term anticoagulation

A. Turpie, A. Spyropoulos, 2005, Current opinion in pulmonary medicine.

Orgaran in the prevention of deep vein thrombosis in stroke patients.

A. Turpie, 1992, Haemostasis.

Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study

B. Eriksson, A. Turpie, S. Schellong, 2007, Journal of thrombosis and haemostasis : JTH.

Other Uses of LMWHs – Miscellaneous

Paolo Prandoni, Mark Levine, Frederick R. Rickles, 1998, Pathophysiology of Haemostasis and Thrombosis.

Survey of cardiac surgeons' perceptions of the addition of ASA to warfarin for patients with mechanical heart valves.

A. Turpie, J. Ray, 1997, The Canadian journal of cardiology.

Epidemiology of Post-Operative Venous Thromboembolismin Asian Countries

A. Turpie, A. Cohen, Ching‐Jen Wang, 2011 .

New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies.

B. Eriksson, A. Turpie, K. Bauer, 2003, Chest.

Gynecology and Obstetrics

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice.

A. Turpie, A. Turpie, 2001, American heart journal.

Patient Management Strategies and Long-Term Outcomes in Isolated Distal Deep-Vein Thrombosis versus Proximal Deep-Vein Thrombosis: Findings from XALIA

W. Ageno, L. Mantovani, A. Turpie, 2019, TH Open.

A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban

Manesh R. Patel, A. Turpie, L. Kwong, 2017, Current medical research and opinion.

Detection of previous proximal venous thrombosis with Doppler ultrasonography and photoplethysmography.

J. Hirsh, A. Turpie, Jeffrey S. Ginsberg, 1989, Archives of internal medicine.

Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial.

M. Gent, A. Turpie, S. Kahn, 2008, Blood.

Prevention of Postthrombotic Syndrome

G. Raskob, A. Nicolaides, M. Griffin, 2013 .

In‐Vitro Studies with Ancrod (‘Arvin’)

A. S. Douglas, A. Turpie, C. Prentice, 1971, British journal of haematology.

The Essence Trial: Efficacy and Safety of Subcutaneous Enoxaparin in Unstable Angina and Non-Q-Wave MI: A Double-Blind, Randomized, Parallel-Group, Multicenter Study Comparing Enoxaparin and Intravenous Unfractionated Heparin: Methods and Design

A. Langer, A. Turpie, E. Gurfinkel, 2004, Journal of Thrombosis and Thrombolysis.

A Randomized Controlled Trial of Low-Molecular-Weight Heparin (Enoxaparin) to Prevent Deep-Vein Thrombosis in Patients Undergoing Elective Hip Surgery

M. Gent, P. Powers, A. Turpie, 1987 .

ATRIAL FIBRILLATION TREATMENT PARADOX: CHARACTERISTICS OF AND FIRST-YEAR EVENTS IN PATIENTS NOT TREATED WITH VITAMIN-K ANTAGONISTS COMPARED TO TREATED PATIENTS. THE GARFIELD REGISTRY

A. Camm, S. Goldhaber, A. Turpie, 2013 .

The safety of antithrombotic therapy during pregnancy

W. Ageno, A. Turpie, S. Crotti, 2004, Expert opinion on drug safety.

The safety of antithrombotic therapy during pregnancy.

W. Ageno, A. Turpie, S. Crotti, 2004, Expert opinion on drug safety.

The top 4 advances in antithrombotic care in the last year.

A. Turpie, 2008, Thrombosis research.

A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions.

S. Mehta, Rizwan Afzal, A. Turpie, 2006, American heart journal.

Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids‐DOTT trial): pilot/feasibility phase findings

J. Halperin, N. Stence, P. Steg, 2015, Journal of thrombosis and haemostasis : JTH.

Warfarin replacements: Mechanisms underlying emerging agents

A. Turpie, 2008 .

Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients

W. Ageno, A. Turpie, A. Spyropoulos, 2012, Thrombosis and Haemostasis.

Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin

T. M. Norris, A. Turpie, Turpie Alexander, 2004, Thrombosis and Haemostasis.

Proceedings: Failure of aspirin and dipyridamole to influence the incidence of leg scan detected venous thrombosis after elective hip surgery.

A. Turpie, J. McBride, V. Kraus, 1975, Thrombosis et diathesis haemorrhagica.

Fondaparinux and prevention of venous thromboembolism after orthopaedic surgery

B. Eriksson, A. Turpie, K. Bauer, 2003, The Lancet.

XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America.

W. Ageno, L. Mantovani, A. Turpie, 2019, Thrombosis research.

Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis.

W. Ageno, L. Mantovani, A. Turpie, 2019, European journal of internal medicine.

Looking forward in the treatment of deep-vein thrombosis.

A. Turpie, A. G. Turpie, 2001, Seminars in hematology.

A multicentre randomised clinical endpoint study of parma 5 computer‐assisted oral anticoagulant dosage

A. Turpie, M. Moia, G. Palareti, 2008, British journal of haematology.

Clinical potential of antithrombotic drugs in coronary syndromes.

A. Turpie, 1998, The American journal of cardiology.

A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.

B. Eriksson, A. Turpie, K. Bauer, 2002, Journal of the Southern Orthopaedic Association.

Fondaparinux.

B. Eriksson, A. Turpie, K. Bauer, 2020, The Journal of the American Academy of Orthopaedic Surgeons.

Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation

A. Camm, D. Atar, D. Fitzmaurice, 2016, Heart.

When and how to use heparin prophylaxis and treatment.

J. Hirsh, A. Turpie, 1979, Geriatrics.

Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry

D. Fitzmaurice, A. Camm, L. Mantovani, 2016, PloS one.

Outpatient thromboprophylaxis after hip or knee surgery: discrepancies and concerns

A. Turpie, W. Fisher, 2008, Canadian Medical Association Journal.

Fondaparinux Sodium

A. Turpie, 2012, Drugs.

ACC Rapid Track Abstract SR 123781 A : A New Once-Daily Synthetic Oligosaccharide Anticoagulant for Thromboprophylaxis After Total Hip Replacement Surgery

A. Turpie, P. Mismetti, O. Dahl, 2008 .

Prevention of venous thrombosis after elective hip surgery.

A. Turpie, A. Kher, 1998, Orthopedics.

Venous Thromboembolism (VTE) Prevention with Semuloparin in Cancer Patients Initiating Chemotherapy: Benefit-Risk Assessment by VTE Risk in SAVE-ONCO

A. Turpie, D. George, G. Agnelli, 2011 .

Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE‐HIP1, SAVE‐HIP2 and SAVE‐KNEE

A. Kakkar, A. Turpie, D. George, 2012, Journal of thrombosis and haemostasis : JTH.

Perioperative Bridging Therapy with Enoxaparin in Patients Requiring Interruption of Long-Term Oral Anticoagulant Therapy: A Multicenter Cohort Study.

A. Turpie, A. Dunn, S. Sirko, 2004 .

Rivaroxaban for Thromboprophylaxis After Fracture-Related Orthopedic Surgery in Routine Clinical Practice

L. Mantovani, A. Turpie, R. Kreutz, 2016, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Can we differentiate the low‐molecular‐weight heparins?

A. Turpie, 2000, Clinical cardiology.

Influence of the duration of fondaparinux (Arixtra®) prophylaxis in preventing venous thromboembolism following major orthopedic surgery

B. Eriksson, A. Turpie, K. Bauer, 2003, Journal of thrombosis and haemostasis : JTH.

Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014.

J. Cairns, A. Turpie, J. Weitz, 2015, Clinical therapeutics.

3001 POSTER DISCUSSION Ultra-low-molecular-weight Heparin (ULMWH) Semuloparin for Prevention of Venous Thromboembolism (VTE) in Cancer Patients Receiving Chemotherapy: Consistent Beneficial Effect Across Cancer Stage and Location Subgroups

A. Turpie, D. George, G. Agnelli, 2011 .

The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study.

A. Turpie, D. George, G. Agnelli, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Effectiveness of Drugs that Modify Platelet Function in Peripheral Venous Thrombosis and Pulmonary Embolism

A. Turpie, 1980 .

Thrombolytic agents in venous thrombosis

A. Turpie, 1990 .

Extended duration of thromboprophylaxis in acutely ill medical patients: optimizing therapy?

A. Turpie, 2007, Journal of thrombosis and haemostasis : JTH.

New Antithrombotic Drugs

W. Ageno, A. Turpie, 2004 .

science [coagulation and hematology]: New Antithrombotic Drugs

W. Ageno, A. Turpie, 2004 .

Critical Care Medical Patients

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis.

Mechanical valves.

G. E. Miller, V. Gott, T. David, 1996, The Annals of thoracic surgery.

Evaluation of a commercial kit for the radioimmunoassay of fibrinopeptide A.

A. Turpie, R. Butt, A. C. deBoer, 1984, Journal of immunoassay.

Prevention of left ventricular mural thrombus.

A. Turpie, 1989, The American journal of cardiology.

Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction: A Meta-Analysis of the Randomized Trials

S. Yusuf, S. Mehta, J. Eikelboom, 2005, Circulation.

Platelet Tests and Antiplatelet Drugs in Coronary Artery Disease

M. Gent, A. Turpie, E. Genton, 1983, Circulation.

The diagnostic value of the fibrinogen/fibrin fragment E antigen assay in clinically suspected deep vein thrombosis.

D. Sackett, J. Hirsh, M. Gent, 1982, Blood.

Treatment of Hypertension with Clonidine

A. Turpie, B. Whiting, W. Maclennan, 1970, British medical journal.

Fondaparinux Combined with Intermittent Pneumatic Compression (IPC) Versus IPC Alone in the Prevention of Venous Thromboembolism after Major Abdominal Surgery: The Randomized APOLLO Study.

M. Gent, A. Turpie, K. Bauer, 2005 .

Thromboprophylaxis after orthopaedic surgery with an oral, direct factor Xa inhibitor: Pooled results of two phase Iib clinical trials.

M. Gent, B. Eriksson, A. Turpie, 2005 .

Efficacy of a postoperative regimen of enoxaparin in deep vein thrombosis prophylaxis.

A. Turpie, 1991, American journal of surgery.

ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION

David Hunt, P Armitage, Sarah Parish, 1992 .

Fondaparinux Reduces Long-term Risk of Venous Thromboembolism After Surgery for Hip Fractur

C. Colwell, B. Eriksson, A. Turpie, 2003 .

What's new for DVT prophylaxis for the medically ill.

W. Ageno, A. Turpie, 2005, Disease-a-month : DM.

Beta-thromboglobulin radioimmunoassay. A laboratory characterization and evaluation.

A. Turpie, W. Walker, E. Genton, 1980, Journal of immunoassay.

THE CANADIAN AMERICAN TICLOPIDINE STUDY (CATS) IN THROMBOEMBOLIC STROKE

V. Hachinski, M. Gent, A. Turpie, 1989, The Lancet.

Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration

B. Eriksson, A. Turpie, K. Bauer, 2003, Thrombosis and Haemostasis.

COMPARISON OF RIVAROXABAN – AN ORAL, DIRECT FACTOR XA INHIBITOR–AND SUBCUTANEOUS ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER TOTAL KNEE REPLACEMENT (RECORD4: A PHASE III STUDY)

M. Gent, A. Turpie, K. Bauer, 2010 .

State of the art--a journey through the world of antithrombotic therapy.

A. Turpie, 2002, Seminars in thrombosis and hemostasis.

Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction.

D. Doyle, J. Cairns, J. Hirsh, 1989, The New England journal of medicine.

Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison

Bengt I Eriksson, B. Eriksson, A. Turpie, 2002, The Lancet.

Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial

Bengt I Eriksson, B. Eriksson, A. Turpie, 2002, The Lancet.

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.

B. Eriksson, A. Turpie, K. Bauer, 2001, The New England journal of medicine.

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.

B. Eriksson, A. Turpie, K. Bauer, 2001, The New England journal of medicine.

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.

R. Califf, M. Cohen, A. Langer, 1997 .

Urokinase Therapy: Dosage Schedules and Coagulant Side Effects

A. S. Douglas, A. Turpie, A. Turpie, 1972, British journal of haematology.

A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery.

J. Hirsh, M. Gent, P. Powers, 1986, The New England journal of medicine.

New oral anticoagulants in atrial fibrillation.

A. Turpie, Alexander G G Turpie, 2007, European heart journal.

Effect in vitro on platelet function of two compounds developed from the pyrimido-pyrimidines

A. S. Douglas, A. Turpie, S. D. Slater, 1972, Journal of clinical pathology.

A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.

A. Turpie, A. Cohen, M. Samama, 1999, The New England journal of medicine.

Patients With Cancer

S. Kakkos, P. Prandoni, G. Raskob, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

High-performance liquid chromatographic determination of dipyridamole.

A. Turpie, J. Rosenfeld, M. Buchanan, 1982, Journal of chromatography.

Dipyridamole disposition after chronic administration: effect of aspirin.

A. Turpie, P. Reilly, J. Rosenfeld, 1983, Thrombosis research. Supplement.

Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry

G. Lip, D. Fitzmaurice, W. Hacke, 2013, PloS one.

Venous thromboembolism: treatment strategies

Gregory Y H Lip, G. Lip, A. Turpie, 2002, BMJ : British Medical Journal.

Clinical trial of deglydyrrhizinized liquorice in gastric ulcer.

A. Turpie, T. J. Thomson, J. Runcie, 1969, Gut.

Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?

R. Hunt, A. Turpie, D. Choquette, 2007, Canadian family physician Medecin de famille canadien.

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation

A. Camm, P. Kirchhof, P. Amarenco, 2015, European heart journal.

Prevention and Treatment of Venous Thromboembolism

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Pathobiologic features and prevention of thrombotic complications associated with prosthetic heart valves: fundamental principles and the contribution of platelets and thrombin.

R. Becker, A. Turpie, P. Eisenberg, 2001, American heart journal.

Studies on East African Snakes

A. S. Douglas, C. Forbes, A. Turpie, 1966, Scottish medical journal.

J. Hirsh, A. Turpie, J. Rosenfeld, 1983, Thrombosis research.

Diagnosis of Venous Thrombosis

M Gent, Aken, J. Hirsh, 2005 .

A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement.

A. Laupacis, J. Hirsh, M. Gent, 1993, The New England journal of medicine.

RANDOMISED COMPARISON OF TWO INTENSITIES OF ORAL ANTICOAGULANT THERAPY AFTER TISSUE HEART VALVE REPLACEMENT

J. Hirsh, M. Gent, A. Turpie, 1988, The Lancet.

Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3)

M. Prins, B. Eriksson, A. Turpie, 2013, Thrombosis and Haemostasis.

The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events

D. Atar, J. Le Heuzey, A. Camm, 2019, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

Comparative effectiveness of oral anticoagulants in everyday practice

A. Camm, D. Fitzmaurice, B. Gersh, 2021, Heart.

Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation

D. Fitzmaurice, S. Goldhaber, J. Eikelboom, 2018, PloS one.

Effect of extended‐duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis

S. Goldhaber, R. Harrington, A. Turpie, 2017, Journal of thrombosis and haemostasis : JTH.

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban

A. Camm, P. Kirchhof, P. Amarenco, 2020, Journal of the American Heart Association.

Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1

A. Turpie, W. Baker, C. Coleman, 2018, European heart journal. Cardiovascular pharmacotherapy.

International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD‐AF, ORBIT‐AF I, and ORBIT‐AF II registries

G. Fonarow, M. Ezekowitz, J. Camm, 2017, American heart journal.

Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation

D. Fitzmaurice, J. Piccini, W. Hacke, 2017, BMJ Open.

Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD‐AF and treated with vitamin K antagonists

D. Fitzmaurice, A. Turpie, G. Accetta, 2016, British journal of haematology.

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF

D. Fitzmaurice, W. Hacke, A. Camm, 2016, European heart journal.

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation

A. Camm, P. Kirchhof, J. Camm, 2014, Vascular health and risk management.

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation

A. Turpie, 2014, Therapeutics and clinical risk management.

Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk

B. Norrving, C. Bode, A. Turpie, 2014, Vascular health and risk management.

International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD).

G. Lip, D. Fitzmaurice, W. Hacke, 2012, American heart journal.

Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF.

A. Camm, L. Mantovani, J. Stȩpińska, 2019, American heart journal.

Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-Analysis of the Literature

G. Lip, W. Ageno, F. Dentali, 2012, Circulation.

GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation

D. Fitzmaurice, J. Piccini, A. Camm, 2021, European heart journal. Quality of care & clinical outcomes.

ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction

Raymond C. Schneider, R. Collins, M. Keltai, 1995, The Lancet.

Bridging therapy in patients on long‐term oral anticoagulants who require surgery: the Prospective Peri‐operative Enoxaparin Cohort Trial (PROSPECT)

A. Turpie, A. Dunn, A. Spyropoulos, 2007, Journal of thrombosis and haemostasis : JTH.

Burden of disease: medical and economic impact of acute coronary syndromes.

A. Turpie, 2006, The American journal of managed care.

Review of enoxaparin and its clinical applications in venous and arterial thromboembolism

A. Turpie, J. Mason, 2002, Expert opinion on pharmacotherapy.

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.

E. Antman, E. Braunwald, C. McCabe, 1999, Circulation.

Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarc

R. Califf, E. DeLong, D. Mark, 1998, Circulation.

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

W. Klein, A. Buchwald, S. Monrad, 1997, Circulation.

Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives

A. Turpie, 2014, Expert review of cardiovascular therapy.

W. Hacke, A. Camm, S. Goldhaber, 2021, Blood advances.

Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-Analysis of the Literature Running title: Dentali et al.; Novel oral anticoagulants in atrial fibrillation

G. Lip, W. Ageno, F. Dentali, 2012 .

Current and Emerging Anticoagulant Agents for the Prevention and Treatment of Ischemic Stroke: Focus on Dabigatran

A. Turpie, K. Webster, 2010 .

Platelet electrophoresis: effect of defibrination by ancrod (Arvin).

A. S. Douglas, A. Turpie, G. Mcnicol, 1972, Cardiovascular research.

Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

S. Goldhaber, A. Turpie, A. Cohen, 2004, Circulation.

Carbenoxolone sodium in the treatment of gastric ulcer with special reference to side-effects.

A. Turpie, T. J. Thomson, 1965, Gut.

Orthopedic Surgery and Trauma

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Predictive and associative models to identify hospitalized medical patients at risk for VTE.

A. Turpie, F. Spencer, M. Monreal, 2011, Chest.

Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.

J. Douketis, J. Hirsh, M. Gent, 2006, JAMA.

Diagnostic efficacy of impedance plethysmography for clinically suspected deep-vein thrombosis. A randomized trial.

Denise H. Kinch, J. Hirsh, H. Büller, 2020, Annals of internal medicine.

Heparin in the Treatment of Thromboembolic Stroke

A. Turpie, R. Bloch, R. Duke, 1989, Annals of the New York Academy of Sciences.

Management Strategies for a Better Outcome in Unstable Coronary Artery Disease

R. Campbell, J. Cleland, C. Conti, 1998, Clinical cardiology.

Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.

G. Raskob, J. Hirsh, M. Gent, 1982, The New England journal of medicine.

Low-molecular-weight heparins in the treatment of acute coronary syndromes.

E. Antman, A. Turpie, Alexander G.G. Turpie, 2001, Archives of internal medicine.

Comparison of Fixed-Dose Weight-Adjusted Unfractionated Heparin and Low-Molecular- Weight Heparin for Acute Treatment of Venous Thromboembolism

J. Douketis, J. Hirsh, M. Gent, 2006 .

Hirudin and thrombosis prophylaxis

A. Turpie, 1996, The Lancet.

A simple, readily available method for risk stratification of patients with unstable angina and non-ST elevation myocardial infarction.

E. Antman, E. Braunwald, A. Bayés de Luna, 2001, The American journal of cardiology.

Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial

P. Deyn, D. Leys, J. Orgogozo, 2001, The Lancet.

Anticoagulants in acute coronary syndromes.

A. Turpie, Alexander G.G. Turpie, 1999, The American journal of cardiology.

Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study

A. Turpie, U. Hoffmann, S. Coccheri, 2010, Journal of thrombosis and haemostasis : JTH.

Predictive value of venous thromboembolism (VTE)‐BLEED to predict major bleeding and other adverse events in a practice‐based cohort of patients with VTE: results of the XALIA study

W. Ageno, L. Mantovani, A. Turpie, 2018, British journal of haematology.

General, Vascular, Bariatric, and Plastic Surgical Patients

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis.

Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study.

A. Turpie, A. Cohen, M. Samama, 2004, Archives of internal medicine.

Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: Methodology for the EXCLAIM study

R. Yusen, A. Turpie, M. Monreal, 2006, Journal of Thrombosis and Thrombolysis.

An Evaluation of d-Dimer in the Diagnosis of Pulmonary Embolism

J. Douketis, P. Brill-Edwards, M. Gent, 2006, Annals of Internal Medicine.

A Randomized Trial of Diagnostic Strategies after Normal Proximal Vein Ultrasonography for Suspected Deep Venous Thrombosis: d-Dimer Testing Compared with Repeated Ultrasonography

J. Douketis, P. Brill-Edwards, M. Gent, 2005, Annals of Internal Medicine.

Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism

A. Turpie, 2012, Therapeutic advances in hematology.

An international multicenter randomized study of computer‐assisted oral anticoagulant dosage vs. medical staff dosage

S Bryan, J Jespersen, A Tripodi, 2008, Journal of thrombosis and haemostasis : JTH.

Prevention and treatment of venous thromboembolism--International Consensus Statement.

P Prandoni, G D Lowe, D Bergqvist, 2013, International angiology : a journal of the International Union of Angiology.

Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada.

A. Panju, A. Turpie, L. Thabane, 2007, Thrombosis research.

Deep venous thrombosis in the medically ill.

W. Ageno, A. Turpie, 2002, Current hematology reports.

Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study

A. Turpie, A. Cohen, M. Samama, 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

DOUBLE-BLIND RANDOMISED TRIAL OF ORG 10172 LOW-MOLECULAR-WEIGHT HEPARINOID IN PREVENTION OF DEEP-VEIN THROMBOSIS IN THROMBOTIC STROKE

J. Hirsh, M. Gent, P. Powers, 1987, The Lancet.

Continued commitment to safety: building on the existing rivaroxaban knowledge base

A. Turpie, J. Beyer-Westendorf, S. Haas, 2015 .

A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment

L. Mantovani, A. Turpie, R. Kreutz, 2013, Thrombosis and Haemostasis.

XANTUS-EL: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America

C. Martinez, A. Turpie, F. Lanas, 2018, The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology.

Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.

A. Turpie, 2004, Surgical technology international.

Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism

A. Turpie, C. Coleman, T. Bunz, 2017, Thrombosis and Haemostasis.

Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.

A. Turpie, D. George, G. Agnelli, 2012, The New England journal of medicine.

Setting a standard for venous thromboembolism prophylaxis.

A. Turpie, 2001, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Idiopathic gangrene in African children.

C. Forbes, A. Turpie, G. Mcnicol, 1967, British medical journal.

Antithrombotics and anticoagulants in coronary syndromes and stroke.

A. Turpie, 2000, Seminars in thrombosis and hemostasis.

Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin.

J. Hirsh, M. Gent, P. Powers, 1991, Annals of internal medicine.

Prevention of venous thromboembolism among hospitalized medical patients.

Samuel Z Goldhaber, S. Goldhaber, A. Turpie, 2005, Circulation.

A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding

M. Gent, B. Eriksson, A. Turpie, 2008 .

Once Daily YM150, an Oral Direct Factor Xa Inhibitor, for Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Hip Replacement.

M. Prins, B. Eriksson, A. Turpie, 2007 .

Antithrombotic Therapy Following Heart Valve Replacement

A. Turpie, 1997, Thrombosis and Haemostasis.

Prophylaxis of venous thromboembolism in stroke patients.

A. Turpie, A G Turpie, 1997, Seminars in thrombosis and hemostasis.

Venous Thromboembolism Risk in Ischemic Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Results From the EXCLAIM Study

R. Yusen, A. Turpie, M. Monreal, 2013, Stroke.

Urologic Surgery

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Cost-Effectiveness of Prevention and Treatment of VTE

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Clinical trials of low molecular weight heparins

A. Turpie, 1999 .

Venous and arterial thrombosis – pathogenesis and the rationale for anticoagulation

C. Esmon, A. Turpie, 2011, Thrombosis and Haemostasis.

Paper1-03 jan 1998

H. Büller, P. Prandoni, A. Turpie, 1997 .

Thrombolytic Therapy in Venous Thrombosis and Pulmonary Embolism

A. Turpie, 1994 .

Influence of Warfarin on Symptoms of Fatigue: Findings of a Randomized Trial

J. Douketis, A. Turpie, S. Kahn, 2005, The Annals of pharmacotherapy.

Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE

W. Ageno, L. Mantovani, A. Turpie, 2017, TH Open.

Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE.

Alfredo E Farjat, W. Ageno, L. Mantovani, 2020, Thrombosis research.

36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE.

Alfredo E Farjat, W. Ageno, P. Prandoni, 2022, Thrombosis research.

Overview of the clinical results of pentasaccharide in major orthopedic surgery.

A. Turpie, 2001, Haematologica.

Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state.

A. Turpie, W. Baker, C. Coleman, 2018, Thrombosis research.

A Computer Generated Induction System for Hospitalized Patients Starting on Oral Anticoagulant Therapy

W. Ageno, A. Turpie, A G Turpie, 2000, Thrombosis and Haemostasis.

O1067 INFLUENCE OF THE DURATION OF FONDAPARINUX PROPHYLAXIS IN PREVENTING VENOUS THROMBOEMBOLISM FOLLOWING HIP FRACTURE SURGERY

B. Eriksson, A. Turpie, K. Bauer, 2004 .

Low-molecular-weight heparin: from the bench to the orthopedic patient.

A. Turpie, 1997, Orthopedics.

Effect of nafazatrom on platelet function and release: relationship to symptomatic episodes in patients with peripheral vascular disease.

A. Turpie, M. Buchanan, R. Butt, 1987, American heart journal.

Stroke severity, early recovery and outcome are each related with clinical classification of stroke: Data from the ‘Tinzaparin in Acute Ischaemic Stroke Trial’ (TAIST)

P. Deyn, D. Leys, E. Ringelstein, 2007, Journal of the Neurological Sciences.

Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE.

A. Turpie, W. Baker, C. Coleman, 2019, The American journal of medicine.

Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial.

A. Turpie, 2000, The American journal of cardiology.

Valvar heart disease and prosthetic heart valves

G. Lip, A. Turpie, I. Goldsmith, 2002, BMJ : British Medical Journal.

Enoxaparin prophylaxis in elective hip surgery.

A. Turpie, 1990, Acta chirurgica Scandinavica. Supplementum.

Exaggerated initial response to warfarin following heart valve replacement.

W. Ageno, A. Turpie, 1999, The American journal of cardiology.

Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry

D. Fitzmaurice, W. Hacke, A. Camm, 2019, International journal of stroke : official journal of the International Stroke Society.

Rivaroxaban for stroke prevention in atrial fibrillation Rivaroxaban : a once-daily oral anticoagulant

A. Turpie, 2014 .

Plasma and urine beta-thromboglobulin concentration in patients with deep vein thrombosis.

A. Turpie, E. Genton, A. D. de Boer, 1981, Blood.

Effectiveness and Safety of Rivaroxaban Vs. Warfarin in Patients with Nonvalvular Atrial Fibrillation and Moderate-to-Severe Chronic Kidney Disease

A. Turpie, R. Kreutz, C. Coleman, 2017 .

Effect of RA233 on Platelet Function In Vitro

A. S. Douglas, A. Turpie, A. A. Hassanein, 1970, British medical journal.

Effect invitro on platelet function oftwocompounds developed fromthepyrimido-pyrimid ines

A. S. Douglas, A. Turpie, S. D. Slater, 1972 .

The cost‐effectiveness of computer‐assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study

S. Bryan, S. Jowett, A. Turpie, 2009, Journal of thrombosis and haemostasis : JTH.

A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program

Stirling Bryan, Leon Poller, Armando Tripodi, 2009, Thrombosis and Haemostasis.

A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy.

W. Ageno, A. Turpie, A G Turpie, 1998, Thrombosis research.

Quantitative Benefit–Risk Assessment of Rivaroxaban for the Prevention of Venous Thromboembolism.

Jesse A. Berlin, Zhong Yuan, Bennett Levitan, 2009 .

Effectiveness of nifedipine GITS in combination with atenolol in chronic stable angina.

M. Motro, P. Erne, A. Turpie, 1999, Canadian Journal of Cardiology.

Significant variation in mortality and functional outcome after acute ischaemic stroke between western countries: data from the tinzaparin in acute ischaemic stroke trial (TAIST)

D. Leys, P. Sørensen, G. Boysen, 2005, Journal of Neurology, Neurosurgery & Psychiatry.

Rivaroxaban - An Oral, Direct Factor Xa Inhibitor - for Thromboprophylaxis after Total Knee Arthoplasty: The RECORD3 Trial.

W. Ageno, A. Turpie, J. Lieberman, 2007 .

Optimizing Prophylaxis of Venous Thromboembolism

A. Turpie, 2002, Seminars in thrombosis and hemostasis.

Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.

C. Howie, M. Gent, P. Gaston, 2010, The Journal of bone and joint surgery. British volume.

Low-molecular-weight heparin: from the bench to the orthopedic patient.

A. Turpie, 1997, Orthopedics.

Future therapeutic directions for factor Xa inhibition in the prophylaxis and treatment of thrombotic disorders.

A. Turpie, 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Benefit of selective factor inhibition.

H. Büller, A. Turpie, 2002, Seminars in thrombosis and hemostasis.

Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan.

C J Carter, G. Raskob, D. Doyle, 1983, Annals of internal medicine.

Thrombolysis with a Combination of Small Doses of Streptokinase and Full Doses of Heparin

M. Gent, A. Turpie, A. Turpie, 1975, Seminars in thrombosis and hemostasis.

Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation

D. Fitzmaurice, S. Goldhaber, J. Eikelboom, 2018, PloS one.

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism.

A. Turpie, C. Coleman, T. Bunz, 2018, The American journal of medicine.

Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism

A. Turpie, C. Coleman, T. Bunz, 2018, Journal of Thrombosis and Thrombolysis.

Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism

A. Turpie, C. Coleman, T. Bunz, 2017, Thrombosis and Haemostasis.

Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.

J. Alpert, J. Copeland, P. Stein, 1992, Chest.

Combined use of leg scanning and impedance plethysmography in suspected venous thrombosis. An alternative to venography.

D. Sackett, J. Hirsh, P. Powers, 1977, The New England journal of medicine.

Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.

J. Alpert, J. Copeland, P. Stein, 1992, Chest.

Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic review

M. Gent, B. Eriksson, A. Turpie, 2004, Journal of thrombosis and haemostasis : JTH.

Thrombophilia

G. Raskob, S. Goldhaber, A. Turpie, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Combined Modalities in Surgical Patients

G. Raskob, A. Nicolaides, M. Griffin, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double‐blind comparison

M. Gent, A. Turpie, K. Bauer, 2007, Journal of thrombosis and haemostasis : JTH.

Clinical Studies: Evidence for Intervention with Specific Antiplatelet Drugs in Arterial Thromboembolism

A. Turpie, 1988, Seminars in thrombosis and hemostasis.

A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.

J. Hirsh, M. Gent, A. Turpie, 1994, Archives of internal medicine.

A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip.

J. Hirsh, M. Gent, P. Powers, 1989, Archives of internal medicine.

Prevention of venous thrombosis by intermittent sequential calf compression in patients with intracranial disease.

J. Hirsh, M. Gent, A. Turpie, 1979, Thrombosis research.

Early recovery and functional outcome are related with causal stroke subtype: data from the tinzaparin in acute ischemic stroke trial.

D. Leys, E. Ringelstein, G. Boysen, 2007, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

Clinical Validity of a Negative Venogram in Patients with Clinically Suspected Venous Thrombosis

D. Sackett, J. Hirsh, D. Taylor, 1981, Circulation.

Unstable angina and non-ST-elevation myocardial infarction: initial antithrombotic therapy and early invasive strategy.

C. Cannon, A. Turpie, 2003, Circulation.

Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery.

J. Hirsh, M. Gent, P. Powers, 1996, Archives of internal medicine.

Medical Patients

G. Geroulakos, A. Turpie, K. Myers, 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE.

Alfredo E Farjat, W. Ageno, P. Prandoni, 2022, Thrombosis research.

Direct Factor Xa and direct thrombin inhibitors: a clinical trial update.

A. Turpie, 2009, Current opinion in drug discovery & development.

Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation

D. Fitzmaurice, S. Goldhaber, J. Eikelboom, 2018, PloS one.

Perioperative management of patients receiving oral anticoagulants: a systematic review.

A. Turpie, A. Dunn, 2003, Archives of internal medicine.

Deep vein thrombosis prophylaxis in the outpatient setting: preventing complications following hospital discharge.

A. Turpie, 1995, Orthopedics.

Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.

J. Alpert, J. Copeland, J. Dalen, 1992, Chest.